Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Dr. Sulaiman Al-Habib Medical Group, Saudi Arabia.
Life Sci. 2022 Dec 1;310:121071. doi: 10.1016/j.lfs.2022.121071. Epub 2022 Oct 12.
When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) may occur, and patients with cancer are at high risk of DDIs because they commonly receive multiple medications. However, data on the prevalence of DDIs are scarce, especially in Saudi Arabia.
Our aim was to evaluate the occurrence of DDIs in patients with cancer and identify risk factors for these DDIs and the clinical outcomes.
A retrospective cross-sectional study was conducted in KFMC. Data were collected from the medical records and phone calls, and the patient's drugs were screened for interactions using Micromedex and Lexi-Comp. The data were statistically analysed using IBM SPSS version 24 statistical program.
In 72 patients (mean age of 47 years; 11 medications), the prevalence of DDIs was 60 %, and 2 potential DDIs were identified. According to Lexi-Comp, 137 (51.8 %) were categorized as pharmacodynamics interactions. In Micromedex, 94 potential DDIs were identified, 68.1 % were categorized as pharmacokinetic interactions, the comparison between the interaction of Lexi-Comp and Micromedex for 9 drugs. Eight drug pairs showed statistically significant difference in category of interaction (P < 0.05). Six pair of drugs showed statistically significant difference in mechanism of action (p < 0.05). Number of drugs was reported as significant risk factor (p = 0.007), type of treatment such as chemotherapy (p = 0.0000) and inpatient admission in terms of length of stay in hospital was also found significant risk factor (p = 0.031).
To prevent DDIs, Physicians and pharmacists should be more aware of these potential interactions to prevent DDIs.
当患者同时使用两种或两种以上药物时，可能会发生药物-药物相互作用（DDI），而癌症患者发生 DDI 的风险很高，因为他们通常会接受多种药物治疗。然而，关于 DDI 发生率的数据很少，尤其是在沙特阿拉伯。
我们旨在评估癌症患者中 DDI 的发生情况，并确定这些 DDI 的危险因素以及临床结局。
在 KFMC 进行了一项回顾性横断面研究。从病历和电话中收集数据，并使用 Micromedex 和 Lexi-Comp 筛查患者的药物是否存在相互作用。使用 IBM SPSS 版本 24 统计程序对数据进行统计分析。
在 72 名患者（平均年龄 47 岁；使用 11 种药物）中，DDI 的发生率为 60%，发现 2 种潜在的 DDI。根据 Lexi-Comp，137 种（51.8%）被归类为药效学相互作用。在 Micromedex 中，确定了 94 种潜在的 DDI，其中 68.1%被归类为药代动力学相互作用，对 9 种药物的 Lexi-Comp 和 Micromedex 相互作用进行了比较。8 种药物对显示出在相互作用类别方面具有统计学显著差异（P<0.05）。6 对药物在作用机制方面显示出统计学显著差异（p<0.05）。药物数量被报道为显著的危险因素（p=0.007），治疗类型，如化疗（p=0.0000）和住院时间的住院天数也被发现是显著的危险因素（p=0.031）。
为了预防 DDI，医生和药剂师应该更加意识到这些潜在的相互作用，以预防 DDI。
